Cargando…

A review of existing neonatal hyperbilirubinemia guidelines in Indonesia

BACKGROUND: Neonatal hyperbilirubinemia is one of the most common conditions for neonate inpatients. Indonesia faces a major challenge in which different guidelines regarding the management of this condition were present. This study aimed to compare the existing guidelines regarding prevention, diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampurna, Mahendra Tri Arif, Pratama, Danny Chandra, Visuddho, Visuddho, Oktaviana, Novita, Putra, Achmad Januar Er, Zakiyah, Rahmi, Ahmad, Jordy Maulana, Etika, Risa, Handayani, Kartika Darma, Utomo, Martono Tri, Angelica, Dina, Ayuningtyas, Wurry, Hendrarto, Toto Wisnu, Rohsiswatmo, Rinawati, Wandita, Setya, Kaban, Risma Karina, Liem, Kian Djien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682606/
https://www.ncbi.nlm.nih.gov/pubmed/38025296
http://dx.doi.org/10.12688/f1000research.110550.2
_version_ 1785151012301963264
author Sampurna, Mahendra Tri Arif
Pratama, Danny Chandra
Visuddho, Visuddho
Oktaviana, Novita
Putra, Achmad Januar Er
Zakiyah, Rahmi
Ahmad, Jordy Maulana
Etika, Risa
Handayani, Kartika Darma
Utomo, Martono Tri
Angelica, Dina
Ayuningtyas, Wurry
Hendrarto, Toto Wisnu
Rohsiswatmo, Rinawati
Wandita, Setya
Kaban, Risma Karina
Liem, Kian Djien
author_facet Sampurna, Mahendra Tri Arif
Pratama, Danny Chandra
Visuddho, Visuddho
Oktaviana, Novita
Putra, Achmad Januar Er
Zakiyah, Rahmi
Ahmad, Jordy Maulana
Etika, Risa
Handayani, Kartika Darma
Utomo, Martono Tri
Angelica, Dina
Ayuningtyas, Wurry
Hendrarto, Toto Wisnu
Rohsiswatmo, Rinawati
Wandita, Setya
Kaban, Risma Karina
Liem, Kian Djien
author_sort Sampurna, Mahendra Tri Arif
collection PubMed
description BACKGROUND: Neonatal hyperbilirubinemia is one of the most common conditions for neonate inpatients. Indonesia faces a major challenge in which different guidelines regarding the management of this condition were present. This study aimed to compare the existing guidelines regarding prevention, diagnosis, treatment and monitoring in order to create the best recommendation for a new hyperbilirubinemia guideline in Indonesia. METHODS: Through an earlier survey regarding adherence to the neonatal hyperbilirubinemia guideline, we identified that three main guidelines are being used in Indonesia. These were developed by the Indonesian Pediatric Society (IPS), the Ministry of Health (MoH), and World Health Organization (WHO). In this study, we compared factors such as prevention, monitoring, methods for identifying, risk factors in the development of neonatal jaundice, risk factors that increase brain damage, and intervention treatment threshold in the existing guidelines to determine the best recommendations for a new guideline. RESULTS: The MoH and WHO guidelines allow screening and treatment of hyperbilirubinemia based on visual examination (VE) only. Compared with the MoH and WHO guidelines, risk assessment is comprehensively discussed in the IPS guideline. The MoH guideline recommends further examination of an icteric baby to ensure that the mother has enough milk without measuring the bilirubin level. The MoH guideline recommends referring the baby when it looks yellow on the soles and palms. The WHO and IPS guidelines recommend combining VE with an objective measurement of transcutaneous or serum bilirubin. The threshold to begin phototherapy in the WHO guideline is lower than the IPS guideline while the exchange transfusion threshold in both guidelines are comparably equal. CONCLUSIONS: The MoH guideline is outdated. MoH and IPS guidelines are causing differences in approaches to the management hyperbilirubinemia. A new, uniform guideline is required.
format Online
Article
Text
id pubmed-10682606
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-106826062023-11-30 A review of existing neonatal hyperbilirubinemia guidelines in Indonesia Sampurna, Mahendra Tri Arif Pratama, Danny Chandra Visuddho, Visuddho Oktaviana, Novita Putra, Achmad Januar Er Zakiyah, Rahmi Ahmad, Jordy Maulana Etika, Risa Handayani, Kartika Darma Utomo, Martono Tri Angelica, Dina Ayuningtyas, Wurry Hendrarto, Toto Wisnu Rohsiswatmo, Rinawati Wandita, Setya Kaban, Risma Karina Liem, Kian Djien F1000Res Research Article BACKGROUND: Neonatal hyperbilirubinemia is one of the most common conditions for neonate inpatients. Indonesia faces a major challenge in which different guidelines regarding the management of this condition were present. This study aimed to compare the existing guidelines regarding prevention, diagnosis, treatment and monitoring in order to create the best recommendation for a new hyperbilirubinemia guideline in Indonesia. METHODS: Through an earlier survey regarding adherence to the neonatal hyperbilirubinemia guideline, we identified that three main guidelines are being used in Indonesia. These were developed by the Indonesian Pediatric Society (IPS), the Ministry of Health (MoH), and World Health Organization (WHO). In this study, we compared factors such as prevention, monitoring, methods for identifying, risk factors in the development of neonatal jaundice, risk factors that increase brain damage, and intervention treatment threshold in the existing guidelines to determine the best recommendations for a new guideline. RESULTS: The MoH and WHO guidelines allow screening and treatment of hyperbilirubinemia based on visual examination (VE) only. Compared with the MoH and WHO guidelines, risk assessment is comprehensively discussed in the IPS guideline. The MoH guideline recommends further examination of an icteric baby to ensure that the mother has enough milk without measuring the bilirubin level. The MoH guideline recommends referring the baby when it looks yellow on the soles and palms. The WHO and IPS guidelines recommend combining VE with an objective measurement of transcutaneous or serum bilirubin. The threshold to begin phototherapy in the WHO guideline is lower than the IPS guideline while the exchange transfusion threshold in both guidelines are comparably equal. CONCLUSIONS: The MoH guideline is outdated. MoH and IPS guidelines are causing differences in approaches to the management hyperbilirubinemia. A new, uniform guideline is required. F1000 Research Limited 2023-11-13 /pmc/articles/PMC10682606/ /pubmed/38025296 http://dx.doi.org/10.12688/f1000research.110550.2 Text en Copyright: © 2023 Sampurna MTA et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sampurna, Mahendra Tri Arif
Pratama, Danny Chandra
Visuddho, Visuddho
Oktaviana, Novita
Putra, Achmad Januar Er
Zakiyah, Rahmi
Ahmad, Jordy Maulana
Etika, Risa
Handayani, Kartika Darma
Utomo, Martono Tri
Angelica, Dina
Ayuningtyas, Wurry
Hendrarto, Toto Wisnu
Rohsiswatmo, Rinawati
Wandita, Setya
Kaban, Risma Karina
Liem, Kian Djien
A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title_full A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title_fullStr A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title_full_unstemmed A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title_short A review of existing neonatal hyperbilirubinemia guidelines in Indonesia
title_sort review of existing neonatal hyperbilirubinemia guidelines in indonesia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682606/
https://www.ncbi.nlm.nih.gov/pubmed/38025296
http://dx.doi.org/10.12688/f1000research.110550.2
work_keys_str_mv AT sampurnamahendratriarif areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT pratamadannychandra areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT visuddhovisuddho areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT oktaviananovita areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT putraachmadjanuarer areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT zakiyahrahmi areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT ahmadjordymaulana areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT etikarisa areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT handayanikartikadarma areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT utomomartonotri areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT angelicadina areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT ayuningtyaswurry areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT hendrartototowisnu areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT rohsiswatmorinawati areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT wanditasetya areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT kabanrismakarina areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT liemkiandjien areviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT sampurnamahendratriarif reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT pratamadannychandra reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT visuddhovisuddho reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT oktaviananovita reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT putraachmadjanuarer reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT zakiyahrahmi reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT ahmadjordymaulana reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT etikarisa reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT handayanikartikadarma reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT utomomartonotri reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT angelicadina reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT ayuningtyaswurry reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT hendrartototowisnu reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT rohsiswatmorinawati reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT wanditasetya reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT kabanrismakarina reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia
AT liemkiandjien reviewofexistingneonatalhyperbilirubinemiaguidelinesinindonesia